Fatemeh Hayati
1, Mohammad Amin Nasouti
1*, Shokhouh Shayanpour
1, Shahla Ahmadi Halili
11 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2 Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Abstract
Baclofen with chemical name of 4-amino-3-(-4-chlorophenyl)-butanoic acid is commonly used to treat dysfunctional voiding, intractable hiccups, palatal myoclonus and for alleviation of signs and symptoms of skeletal muscle spasticity and spasm. It is also currently used to treat trigeminal neuralgia, addiction to opiates, alcohol, or cocaine and for alleviation of pain among patients with multiple sclerosis or in patients with spinal or cerebral disorders. In individuals with disturbed kidney function and particularly in the patients with end-stage renal disease (ESRD), the accumulation of the drug is occurred and the half-life of the drug is prolonged which can lead to significant side effects and complication including neurological deterioration and coma.
Citation: Hayati F, Nasouti MA, Shayanpour S, Ahmadi Halili S, Nasouti A. Administration of baclofen in end-stage renal disease. J Renal Endocrinol. 2017;3:e02. DOI: 10.15171/jre.2017.02.
Implication for health policy/practice/research/medical education
In individuals with disturbed kidney function and particularly in the patients with end-stage renal disease (ESRD), the accumulation of the drug is occurred and the half-life of the drug is prolonged which can lead to significant side effects and complication including neurological deterioration and coma.